VIRX (Viracta Therapeutics) Accounts Payable: $1.82 Mil (As of Sep. 2024)


What is Viracta Therapeutics Accounts Payable?

Viracta Therapeutics VIRX Accounts Payable is $1.82 Mil as of Sep. 2024.

Viracta Therapeutics's Accounts Payable for the quarter that ended in Sep. 2024 was $1.82 Mil.

Viracta Therapeutics's quarterly Accounts Payable declined from Mar. 2024 ($2.41 Mil) to Jun. 2024 ($1.29 Mil) but then increased from Jun. 2024 ($1.29 Mil) to Sep. 2024 ($1.82 Mil).

Viracta Therapeutics's annual Accounts Payable declined from Dec. 2021 ($2.90 Mil) to Dec. 2022 ($2.54 Mil) and declined from Dec. 2022 ($2.54 Mil) to Dec. 2023 ($2.44 Mil).

Viracta Therapeutics Accounts Payable Related Terms

Viracta Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Accounts Payable Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accounts Payable
1.56 2.90 2.54 2.44

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.36 2.44 2.41 1.29 1.82

Viracta Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.82 Mil mean?
Viracta Therapeutics (VIRX) has a Accounts Payable of $1.82 Mil as of Sep. 2024. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Accounts Payable too high?
Viracta Therapeutics' current Accounts Payable is $1.82 Mil.
How does Viracta Therapeutics' Accounts Payable compare to TSOI and CYTOF?
Viracta Therapeutics' Accounts Payable of $1.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current Accounts Payable is $1.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Accounts Payable of $1.82 Mil. The current Accounts Payable is $1.82 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Accounts Payable is $1.82 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.